Deucravacitinib is a selective, allosteric TYK2 inhibitor that blocks IL-12, IL-23 and type I interferon signalling, approved for moderate-to-severe plaque psoriasis and distinguishing itself from JAK inhibitors through its pseudokinase-domain binding mechanism. Simson Pharma's Deucravacitinib reference standard and impurities support analytical development for this novel dermatology target.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Deucravacitinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.